Clinical impact of PET/MRI in oligometastatic colorectal cancer. British journal of cancer Furtado, F. S., Suarez-Weiss, K. E., Vangel, M., Clark, J. W., Cusack, J. C., Hong, T., Blaszkowsky, L., Wo, J., Striar, R., Umutlu, L., Daldrup-Link, H. E., Groshar, D., Rocco, R., Bordeianou, L., Anderson, M. A., Mojtahed, A., Qadan, M., Ferrone, C., Catalano, O. A. 2021

Abstract

BACKGROUND: Oligometastatic colorectal cancer (CRC) is potentially curable and demands individualised strategies.METHODS: This single-centre retrospective study investigated if positron emission tomography (PET)/magnetic resonance imaging (MR) had a clinical impact on oligometastatic CRC relative to the standard of care imaging (SCI). Adult patients with oligometastatic CRC on SCI who also underwent PET/MR between 3/2016 and 3/2019 were included. The exclusion criterion was lack of confirmatory standard of reference, either surgical pathology, intraoperative gross confirmation or imaging follow-up. SCI consisted of contrast-enhanced (CE) computed tomography (CT) of the chest/abdomen/pelvis, abdominal/pelvic CE-MR, and/or CE whole-body PET/CT with diagnostic quality (i.e. standard radiation dose) CT. Follow-up was evaluated until 3/2020.RESULTS: Thirty-one patients constituted the cohort, 16 (52%) male, median patient age was 53 years (interquartile range: 49-65 years). PET/MR and SCI results were divergent in 19% (95% CI 9-37%) of the cases, with PET/MR leading to management changes in all of them. The diagnostic accuracy of PET/MR was 90±5%, versus 71±8% for SCI. In a pairwise analysis, PET/MR outperformed SCI when compared to the reference standard (p=0.0412).CONCLUSIONS: These findings suggest the potential usefulness of PET/MR in the management of oligometastatic CRC.

View details for DOI 10.1038/s41416-021-01494-8

View details for PubMedID 34282295